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Hutchinson–Gilford progeria syndrome (HGPS) is a rare genetic disorder phenotypically characterized by
many features of premature aging. Most cases of HGPS are due to a heterozygous silent mutation
(c.1824C>T; p.Gly608Gly) that enhances the use of an internal 5′ splice site (5′SS) in exon 11 of the LMNA
pre-mRNA and leads to the production of a truncated protein (progerin) with a dominant negative effect.
Here we show that HGPS mutation changes the accessibility of the 5′SS of LMNA exon 11 which is seques-
tered in a conserved RNA structure. Our results also reveal a regulatory role of a subset of serine–arginine
(SR)-rich proteins, including serine–arginine rich splicing factor 1 (SRSF1) and SRSF6, on utilization of the
5′SS leading to lamin A or progerin production and a modulation of this regulation in the presence of the
c.1824C>T mutation is shown directly on HGPS patient cells. Mutant mice carrying the equivalent mutation
in the LMNA gene (c.1827C>T) also accumulate progerin and phenocopy the main cellular alterations and
clinical defects of HGPS patients. RNAi-induced depletion of SRSF1 in the HGPS-like mouse embryonic fibro-
blasts (MEFs) allowed progerin reduction and dysmorphic nuclei phenotype correction, whereas SRSF6
depletion aggravated the HGPS-like MEF’s phenotype. We demonstrate that changes in the splicing ratio be-
tween lamin A and progerin are key factors for lifespan since heterozygous mice harboring the mutation lived
longer than homozygous littermates but less than the wild-type. Genetic and biochemical data together favor
the view that physiological progerin production is under tight control of a conserved splicing mechanism to
avoid precocious aging.
INTRODUCTION
Different proteins are produced by alternative splicing and or
polyadenylation of the LMNA gene, including lamin A, lamin
C and progerin (Fig. 1A) (1–5). Lamin A and lamin C are
major components of the nuclear lamina, a complex molecular
interface located between the inner membrane of the nuclear
envelope and chromatin (6). Lamins A and C are also distributed
throughout the nucleoplasm and are involved in crucial func-
tions, including DNA replication, transcription, chromatin or-
ganization, nuclear positioning and shape, as well as the
assembly/disassembly of the nucleus during cell division (6–8).
Hutchinson–Gilford progeria syndrome (HGPS) is a dominant
disease usually caused by heterozygous de novo mutations in the
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LMNAgene that leads to accumulation of a truncated protein, com-
monly called progerin (4,5). Progerin is hardly detectable in wild-
type (WT) cells but a single nucleotide substitution c.1824C.T,
recurrent in the majority of typical HGPS patients, promotes acti-
vation of a 5′ splice site (5′SS) in exon 11, causing a large increase
in the levels of transcripts encoding progerin compared with the
other LMNA isoforms. Due to a 150 nucleotides deletion from
exon 11, progerin retains the C-terminal CAAX box of lamin A
(encoded by exon 12), which undergoes methyl esterification
and farnesylation, but it lacks 50 internal amino acids essential
for a specific cleavage step involved in lamin A maturation
(4–11). Progerin is therefore permanently farnesylated and car-
boxymethylated (12,13) which leads to its abnormal anchoring
to the nuclear membrane throughout the cell cycle (13,14). The
production of progerin interferes with the integrity of the nuclear
lamina, causing misshapen nuclei, and also adversely affects
other important cellular processes, such as interphase chromatin,
mitosis and cell proliferation (4,5,10,11,14). The finding that pro-
gerin is expressed at detectable levels in healthy individuals and
seems to accumulate with age has led to the proposal that progerin
could be involved in physiological aging (10,15–17). However, to
date very little is known about the underlying splicing mechanism
leading to usage of the internal 5′SS in exon 11 and how this selec-
tion might alter lifespan.
Major players in both splice-site recognition and intron excision
are five small nuclear RNAs (U1, U2, U4, U5 and U6) which have
dynamic specific interactions via base pairing with the pre-mRNA
(18), and notable among these are the base pairing between U1
snRNA and the 5′SS. However, the information contained in the nu-
cleotide sequence in splice sites is not sufficient for regulation and it
has been shown that the RNA–protein complexes which form on
the pre-mRNA also help the recognition of exons (19). The majority
of splicing regulatoryproteins in these complexes belongs to the het-
erogeneous ribonucleoprotein (hnRNP) and serine–arginine
(SR)-protein families. HnRNPs were initially defined as the major
proteins binding to RNA polymerase II transcripts in the course of
transcription. SR proteins containing arginine-serine rich domains
play essential roles in the splicing reaction (19–22). HnRNPs and
SR proteins contain both RNA-binding and protein–protein inter-
action domains. They bind with low specificity to accessible parts
of the pre-mRNA and RNA secondary structures strongly influence
their binding efficiency (23–27).
Here we use in vitro and in vivo approaches to explore the
sharp differences in splice-site usage in progeria patients. By
probing the conserved structure of the alternatively spliced
RNA as well as the proteins that bind to it, we demonstrate
that the c.1824C.T mutation increases the accessibility of the
exon 11 internal 5′SS which should facilitate U1 snRNP
binding and discover a previously undescribed repression by
the SR protein serine–arginine rich splicing factor 6 (SRSF6),
whereas SRSF1 has an opposite action. Thus RNA-binding pro-
teins and RNA structure should cooperate with enhanced U1
complementarity in the regulation of production of the progerin.
Additionally, mouse embryonic fibroblasts (MEFs) that harbor a
synonymous C.T (GGC.GGT, Gly609Gly) single-base sub-
stitution of the mouse Lmna gene demonstrate that this splicing
mechanism is conserved from the mouse to human and is deter-
minant in the control of lifespan.
RESULTS
Conserved RNA structure at the progerin 5′SS
The synonymous c.1824 C.T (GGC.GGT, G608G) single-
base substitution in exon 11 of the LMNA gene that potentiates
Figure 1. LMNA isoforms and properties of the progerin and lamin 5′SSs. (A)
Three different proteins are produced from the LMNA gene. Cartoon showing
the exon structure of the three different forms of LMNA mRNA showing the
position of the alternative splice site used in progerin and alternative polyaden-
lyation site that is specific for lamin C. Exons are numbered and shown as
boxes (coding regions are solid). Introns are shown as lines. The site of the
HGPS mutation is shown in bold. (B) The HGPS progeria mutations increase
complementarity of the progerin splice site for U1 snRNA. The wild type and
mutant progerin 5′SSs are shown based paired to U1 snRNA sequence. The
mutation creates an AU base pair at the plus 6 position shown in bold. (C) Pre-
dicted bioinformatic scores of the LMNA splice sites. Bioinformatic scores for
a consensus splice site (consensus 5′SS), lamin A 5′SS, the progerin 5′SS and
the mutants c.1824C.T and c.1822G.A progerin 5′SS are shown using two
different programs. Note the near-perfect score of the lamin 5′SS and the mod-
erate improvement in the mutated progerin 5′SS+ 1824C.T compared with
WT progerin 5′SS.
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usage of the exonic 5′SS (hereafter referred to as the progerin
5′SS) is not expected to have a strong effect on splicing
because it occurs at the final, highly variable (+6) position
of the 5′SS consensus (25,26,28–30). Furthermore, computa-
tional analyses to score the strength of either the WT or the
mutated (c.1824C.T) form of the progerin 5′SS in compari-
son with the downstream ‘authentic’ 5′SS that is used to
produce lamin A (hereafter referred to as the lamin A 5′SS)
revealed that the scores of the progerin 5′SS are lower than
the lamin A 5′SS (Fig. 1A–C). While the c.1824C.T muta-
tion augments the score of the progerin 5′SS, it is not sufficient
to make it comparable to the lamin A 5′SS which has a close to
perfect score (Fig. 1B and C). However, the mutation results in
the production of more progerin mRNA than lamin A mRNA
(see below), suggesting that the mutation likely enhances rec-
ognition of the progerin 5′SS by other mechanisms than
simply by enhancing base pairing with U1 snRNP. Given
the fact that RNA structure may be essential for the interaction
of a target pre-mRNA and spliceosomal components, and
thereby may influence splice-site selection (20,31,32), we
decided to assay for disruption or occurrence of RNA struc-
tures surrounding the c.1824C.T mutation in exon 11 of
the LMNA gene. To this end, radiolabelled RNAs were tran-
scribed, denatured and refolded and then digested with differ-
ent ribonucleases specific either for accessible single-stranded
regions (T1 and T2 RNAses) or for double-stranded or stacked
RNA regions (V1 RNase). To avoid border effects, the sites of
cleavage were analyzed by primer extension on a series of
overlapping fragments of different sizes. The most stable sec-
ondary structure that fits the best with the experimental data
was predicted with the M-fold software by introducing experi-
mental data as constraints. In all RNA fragments studied, the
segment from positions 1804–1851, which contains the pro-
gerin 5′SS was always folded into a compact 2-D structure
(Fig. 2A) with the progerin 5′SS located in the stem. This
part of stem-loop (SL) structure IV will now be denoted as
the progerin stem-loop (progerin SL). Its terminal tetra-loop
is expected to be structured because of its limited accessibility
to RNases. In contrast, the lamin A 5′SS was found to be
located in a highly accessible single-stranded region in all
the RNA fragments studied (Fig. 2A and Supplementary
Material, Fig. S1). Thus, in contrast to the lamin A 5′SS, rec-
ognition of the progerin 5′SS in the WT gene is normally dis-
favored due to its sequestration in a structured region.
Interestingly, when repeating the experiment on transcripts
containing the c.1824C.U mutation, we found that the pro-
geria mutation induces some opening of the progerin SL ter-
minal loop which flanks the progerin 5′SS, as shown by the
strong accessibility to T1 RNase (Fig. 2B, right panel).
Although the mutation is not expected to affect the base
pairing of the stem structure, the stability of the terminal
G-C pair may be also slightly decreased based on the appear-
ance of some T2 RNase cleavage 3′ to residue C1828 (Fig. 2B,
right panel). The overall conformational change of the pro-
gerin SL might therefore increase the accessibility of the pro-
gerin 5′SS to U1 snRNA and explain, at least in part, the
increased usage of this site in HGPS.
To further analyze the unexpected accessibility of the loop
of the progerin SL after the c.1824C.U mutation, we decided
to assess two novel mutations, one located in the stem and
expected to alter RNA structure of the region and a second
in the loop of the progerin SL, as the original mutation. The
first is a HGPS mutation, which significantly increased the
complementarity of the progerin 5′SS with U1 snRNA
(Fig. 1), and was also found to increase utilization of the pro-
gerin 5′SS (4,5). By probing the structure of the mutated
pre-mRNA region with T1 and T2 RNases, we observed an
opening of the terminal loop in the progerin SL (Supplemen-
tary Material, Fig. S2a). The G.A mutation disrupts a G–C
base pair close to the WT terminal loop and as a consequence
several G residues are cleaved by T1 RNase within the opened
terminal loop. A better accessibility of the 5′SS region, to-
gether with an increased complementarity to the U1 snRNA,
may explain the strong utilization of the progerin 5′SS in the
b-globin-LMNA reporter RNA incubated in HeLa nuclear
extract (see below and Supplementary Material, Fig. S2b).
For the second mutation, we replaced the first residue of the
loop, residue G1825 which is located 3′ to the U1 binding site
into an A residue and tested for the effect on both RNA struc-
ture and utilization of the progerin 5′SS (Supplementary Ma-
terial, Fig. S2a and b). Interestingly, this mutation increased
both the accessibility of the loop to RNases (especially
RNase T2) and the utilization of the progerin 5′SS (Supple-
mentary Material, Fig. S2a and b). Altogether with the muta-
tion c.1824C.U data, these data show a possible correlation
between the accessibility of the terminal loop of the progerin
SL and the efficiency of the progerin 5′SS utilization.
Recognition of the progerin 5′SS by the SR proteins
SRSF1 and SRSF6
Mutations responsible for splicing defects at the origin of
human diseases are either found in splice sites, or in regulatory
sequences involved in the control of splicing (25,28,33–35).
Therefore, we used various approaches to investigate
whether the c.1824C.T mutation might modify the binding
of some splicing regulatory factors at or in the vicinity of
the progerin 5′SS, in addition to its effect on the RNA
structure.
First, we identified nuclear proteins able to bind to the
progerin SL structure by fusing three MS2 coat protein RNA-
binding sites at the 3′ extremity of the progerin SL RNA (Sup-
plementary Material, Fig. S3a) and purifying the complexes
formed by incubation of the tagged RNA in HeLa nuclear
extract. The complexes were affinity purified using an MS2
coat protein fused to the Maltose Binding Protein bound to
amylose beads, as previously described (36,37). Both mass
spectrometry analysis of protein bands purified from sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS–
PAGE) and western blot analysis (Supplementary Material,
Fig. S3b) of the bound proteins revealed the presence of the
SR proteins SRSF1 and SRSF6. The association of both pro-
teins was also observed when using a longer RNA called pro-
gerin ESL (Extended Stem Loop) which contains stem loops
III, IV and V in addition to progerin SL, and association of
SRSF6 was stronger with this longer RNA (see Fig. 1 and
Supplementary Material, Fig. S3a). Interestingly, experiments
done with SL or ESL RNAs containing the c.1824 C.U
mutation revealed that SRSF1 association with each of the
mutated progerin SL and ESL RNAs was strongly diminished,
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whereas association of SRSF6 with the SL RNA was dimin-
ished to a lower degree, but its association with the ESL
RNA was also more extensively reduced (Supplementary Ma-
terial, Fig. S3b). Altogether, this revealed another property of
the mutated RNA which may influence progerin 5′SS utiliza-
tion. However, based on gel shift experiments performed with
recombinant SRSF1 and an in vitro transcribed progerin SL
structure, the affinity of the isolated protein SRSF1 for the
WT RNA is low, suggesting that its association in the
extract is mediated or reinforced by the presence of some
other proteins (Supplementary Material, Fig. S3c).
Therefore, to identify proteins that bind directly to the
segment containing the progerin 5′SS, we performed UV cross-
linking experiments using 32P-labeled RNA probes. Probe WT
of 21 nucleotides contains the progerin 5′SS and corresponded
to the upper part of the progerin SL (Figs 2A and 3A). The
mutated probe (Mut) included the c.1824C.T mutation.
Probes were cross-linked in 293E and HeLa cells nuclear
extracts, or in nuclear extract fraction precipitated with magne-
sium which is one of the steps used in SR protein purification
(38). Labeled proteins were analyzed by electrophoresis on
SDS–polyacrylamide gels after RNase treatment and visualized
by autoradiography. Using whole nuclear extracts, WT probe
predominantly cross-linked to proteins with apparent molecular
weights of 30, 55 and 120 kDa, whereas only 55 and 120 kDa
protein bands are revealed with the Mut progerin probe
(Fig. 3B, lanes 1 and 4). However, only two main bands at 55
and 30 kDa were detected when UV-cross-linking was per-
formed with the MgCl2-enriched SR protein fraction (Fig. 3C,
lanes 3 and 6). According to their electrophoretic mobility, the
Figure 2. Secondary structure around LMNA exon 11 splice sites. (A) The secondary structure model proposed for exon 11 and part of intron 11 of the human
LMNA pre-mRNA. The model is proposed based on thermodynamic considerations and on the results of enzymatic digestions shown in Supplementary Material,
Figure S1. V1, T1 and T2 RNase cleavages are represented by arrows surmounted by squares, dots and diamonds, respectively. Red, orange and green symbols
indicate a high, medium or low extent of cleavage, respectively. The structure representation shows all the bases used and the position of the splice sites are
indicated with arrows. Different predicted SL structures are numbered with roman numerals. Note that the lamin A 5′SS is in a single-stranded conformation,
whereas the Progerin 5′SS is engaged in a secondary structure (referred to in the text as progerin SL). (B) The progeria mutation opens RNA structure around the
progerin 5′SS. Autoradiographs show primer extension analyses of the WT progerin 5′SS and the mutant c.1824C.U progerin 5′SS cleaved by increased amount
of T1 and T2 RNases. Lanes U, G, C and A correspond to the sequencing ladder. The dotted line at the level of the terminal G–C pair indicates that the stability
of this terminal pair may be slightly decreased in the presence of the progeria mutation based on the appearance of some T2 RNase cleavage 3′ to residue C1828.
Figure 3. The SR proteins SRSF1 and SRSF6 cross-link to the WT and the c.1824C.U mutant progerin SL. (A) Sequences of the RNA constructs used for
cross-linking in nuclear extracts. The sequences shown were embedded within a 40 mer RNA with invariable flanking sequences. The different RNA probes
comprise monomers (1X) of the progerin 5′SS contained in the SL structure in the wild-type (WT 1X) or mutated versions (Mut 1X). (B) Cross-linking
assay in nuclear extract of untransfected cells (lanes 1 and 4) or transfected cells expressing flag-tagged SRSF6 (lanes 2 and 5) or His-tagged SRSF1 (lanes
3 and 6). The constructs (detailed in A) were cross-linked in different nuclear extracts and after RNase cleavage bound proteins were separated by SDS–
PAGE and visualized by autoradiography. The size of the protein markers is shown on the left. (C) The cross-linking experiment (detailed in B) was repeated
but with HeLa nuclear extract (HeLa NE, lanes 1 and 4) or with supernatant of HeLa nuclear extract treated with 30 mM MgCl2 and centrifugation (lanes 2 and 5)
or with the 30 mM MgCl2 precipitation-enriched nuclear extract (lanes 3 and 6). (D) 2D gel analysis of UV-cross-links using the mutated version of the progerin
SL probe and HeLa nuclear fraction that precipitates at 30 mM MgCl2. This gel was transferred to a nitrocellulose membrane and submitted to autoradiography
and then probed with antibodies specific for SRSF6 and SRSF1.
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proteins cross-linked to the progerin probes might be the SR pro-
teins SRSF6 and one of the SRp30 proteins. Since the labeling of
the 30 kDa band was decreased with the mutated RNA probe, it
might represent SRSF1, which binding to the mutated progerin
SL also decreased (Supplementary Material, Fig. S3). However,
binding to other SRp30 proteins migrating at the same position
of the gel (notably SRSF2 or SRSF7) cannot be completely rule
out.
This identification was further confirmed by UV-cross-
linking experiments performed with extracts from cells
expressing tagged SRSF1 (His-SRSF1) or SRSF6 (Flag-
SRSF6). Both tagged proteins were efficiently cross-linked,
consistent with their expected apparent mobility (Fig. 3B,
lanes 2, 3, 5 and 6) and were immunoprecipitated with the cor-
responding anti-tag antibodies (data not shown). Another con-
firmation was obtained by analyzing the cross-linked products
with the WT RNA probe by two-D gel electrophoresis fol-
lowed by western blotting. The 55 and 30 kDa cross-link
signals coincided with different phosphorylation isoforms
revealed by specific antibodies directed against SRSF6 and
SRSF1, respectively (Fig. 3D, compare upper panel with
SRSF1 and SRSF6 panels, respectively). To further document
the specificity of the cross-linking, we tested two control
probes under the same conditions: the RSF1 BS probe,
which is a high-affinity binding site for RSF1 (RNA splicing
repressor 1) known to bind hnRNP sequences (39), and the
SRSF1 probe which is a high-affinity binding site for SRSF1
and other SR proteins (39). None of the probes demonstrated
a strong signal at 55 kDa similar to the progerin SL probe
(data not shown).
All the data of Figure 3 establish that the progerin SL and
ESL RNAs have the ability to bind to SRSF1 and SRSF6. In
these experiments, when protein SRSF1 was over-expressed,
no significant decrease in the SRSF1 cross-link was detected
in the presence of the mutation (Fig. 3B). However, in the
presence of a more limited amount of SRSF1 (Fig. 3C and
Supplementary Material, Fig. S3), the mutation was found to
limit binding of SRSF1 to the RNA.
The SR protein SRSF6 represses splicing to the progerin
5′SS in vitro
To assess the contribution of the SRSF1 and SRSF6 splicing
factors to progerin production, we cloned the LMNA
genomic sequence from exons 11 through 12 with or
without the HGPS mutation in a reporter construct that was
suitable for both cell transfection and in vitro splicing assays
(Fig. 4A). In the presence of the HGPS mutation, transient
transfections of these constructs in HeLa cells gave rise to a
150 nucleotide deletion in the LMNA splicing product due to
the predominant use of the progerin 5′SS, whereas only the
lamin A 5′SS was selected when using the WT LMNA reporter
(Fig. 4B). In contrast, when the same constructs were used in
in vitro splicing experiments (Fig. 4C), both the WT and
mutated LMNA substrates led to the production of mRNAs
arising from the utilization of both lamin A and progerin
5′SSs, implying that the progerin 5′SS can be recognized in
the extract as an authentic 5′SS, even in the absence of the
HGPS mutation. However, splicing in RNAs transcribed
from the mutated LMNA construct predominantly used the
progerin 5′SS, whereas in RNA of the WT LMNA construct
splicing mostly proceeded through the lamin A 5′SS
(Fig. 4C, compare lanes 4–7 and lanes 11–14). Depletion of
the U1 snRNP from the extract abolished usage of both pro-
gerin and lamin A 5′SSs and led to exon 11 skipping (data
not shown), implying that both splice sites are equally depend-
ent on U1 snRNP. This result also indicate that exon 12 of
LMNA may assemble a cross exon complex able to subse-
quently bind the globin 5′SS to generate a B-like spliceosomal
complex to perform splicing independently of U1 as has
recently been suggested by Schneider et al. (40).
To test whether SRSF1 or SRSF6 might be involved in
activation of the utilization of the progerin 5′SS, in vitro spli-
cing assays were performed with HeLa cell nuclear extracts
supplemented with recombinant SRSF1 or SRSF6 proteins
(Fig. 4D). An expected effect of the addition of a SR protein
is to increase the global splicing activity of the nuclear
extract. However, SRSF6 addition strongly inhibited the use
of the progerin 5′SS, whereas the selection of the lamin A
5′SS was activated (Fig. 4D, compare lane 2 with lanes
3–4). Addition of SRSF1 to the extract also resulted in less
progerin and more lamin A mRNA production from the WT
substrate. But this effect was milder than that observed with
SRSF6 (Fig. 4D, lanes 9–10). Similar effects of both SR
proteins were obtained with the mutated LMNA transcript
(Fig. 4D, lanes 6–7 and 12–13, respectively). However,
SRSF6 had a very strong inhibition activity on the use of
the mutated progerin 5′SS in the mutated RNA, whereas
Figure 4. SRSF1 and SRSF6 play opposite roles in LMNA splicing. (A) Schematic representation of the minigene reporters b globin-LMNA used for the study of
LMNA splicing. LMNA sequences, carrying (Mut) or not carrying (Wt) the mutation, were inserted downstream of sequences derived from the human b globin
gene. (B) These minigenes were transfected into HeLa cells and the splicing products were analyzed by RT–PCR of RNA extracted from transfected cells using
primers either side of the alternatively spliced regions that give different sized products for the long and short forms. (C) Time course of in vitro splicing of WT
and Mut reporters showing differential but significant use of both lamin A 5′SS and progerin 5′SS in HeLa nuclear extracts. RNA size markers are indicated on
the left. Different times of incubation in minutes are indicated on the top of each panel. (D) Splicing reactions with Wt (lanes 1–4 and 8–10) and Mut (lanes 5–7
and 11–13) reporters in HeLa nuclear extracts alone (lanes 2, 5, 8 and 11) or supplemented with either SRSF6 (lanes 3–4 and 6–7) or SRSF1 (lanes 9–10 and
12–13) recombinant proteins [200 ng (lanes 3, 6, 9 and 12) or 400 ng (lanes 4, 7, 10 and 13)]. (Star) Note that a minor mRNA species of 450 nt long which
accumulates in the presence of SRSF6 corresponds to the use of a cryptic 5′SS. (E) Splicing reactions with WT (lanes 1–6) and Mut (lanes 7–11) reporters
mutated at lamin 5′SS in HeLa nuclear extracts alone (lanes 2 and 7, respectively) or supplemented with either SRSF6 (lanes 5–6 and 10–11) or SRSF1
(lanes 3–4 and 7–8) recombinant proteins [200 ng (lanes 3, 5, 8 and 10) or 400 ng (lanes 4, 6, 9 and 11)]. The relative efficiency of splicing is indicated
below each panel, with a value of 100 for the assays without added SR protein. (F) Depletion of SRSF1 or SRSF6 in Hela cells using siRNAs was assessed
by western blotting and (G) resulting mRNA levels assessed by RT–qPCR. (H) The splicing pattern of the mutant b globin-LMNA reporter in treated cells
was determined by RT–PCR using primers either side of the alternative spliced region as in (B) and (I) quantification of the ratio between truncated and full-
length isoforms from three independent experiments of SRSF1 and SRSF6 siRNA knockdown. The value of 1 is arbitrarily assigned to control siRNA samples.
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SRSF1 was unable to inhibit it completely. Also, SRSF6
highly activated the use of the lamin A 5′SS (Fig. 4D, lanes
6–7).
As these experiments could not discern whether SRSF6 acts
as a repressor of the progerin 5′SS and/or as an activator of the
lamin A 5′SS, we mutated the first G of the lamin A 5′SS in
the WT and mutated substrates and tested the effect of
SRSF6. Addition of SRSF6 to the extract inhibited strongly
progerin mRNA production in the WT and the mutant
context (Fig. 4E, compare lanes 2 and 7 with lanes 5–6 and
lanes 10–11, respectively). In contrast, addition of SRSF1
had a mild effect in the WT context, and almost no effect in
the presence of the c.1824C.T mutation (Fig. 4E, compare
lanes 2 and 7 with lanes 3–4 and lanes 8–9, respectively),
which is in agreement with its lower association with the
mutated progerin SL RNA in HeLa nuclear extract. Taken
together, the data suggest that the SRSF1 activity mainly con-
sists in the activation of the lamin A 5′SS, while SRSF6 acts as
a repressor of progerin production, most probably by binding
to the progerin SL sequence and may be also by an
independent activation of the lamin A 5′SS.
The SR protein SRSF6 represses the usage of the progerin
5′SS in transfected cells
If SRSF6 plays an important role in repressing the progerin
5′SS in vivo, it should be possible to reverse this phenomenon
by decreasing SRSF6 levels. This possibility was next investi-
gated by using small-interfering RNAs (siRNAs) to reduce the
amount of SRSF6 in HeLa cells transfected with the mutant
LMNA minigene, for which the selection of the progerin
5′SS is predominant. Treatment of HeLa cells with siRNAs
targeting SRSF6 resulted in a large and specific reduction in
the SRSF6 level, as observed 96 h post-transfection by
western blotting (Fig. 4F). Under the same conditions, no sig-
nificant changes were observed in the expression of SRSF1
and g-tubulin, used as internal controls (Fig. 4F). Quantitative
polymerase chain reaction (PCR) analysis also confirmed that
SRSF6 expression was reduced at the RNA level (Fig. 4G).
The effect of SRSF6 depletion on the splicing profile of the
HGPS mutant LMNA minigene was analyzed by reverse tran-
scription polymerase chain reaction (RT–PCR), using primers
allowing discrimination between mRNAs spliced at the lamin
A and the progerin 5′SSs, respectively (Fig. 4H). Results from
three independent experiments showed that the siRNA-
mediated reduction in the SRSF6 protein level greatly
enhanced usage of the progerin 5′SS (Fig. 4H and I),
whereas utilization of the lamin A 5′SS remained unchanged.
Surprisingly, siRNA knockdown of SRSF1 to comparable
levels of SRSF6 knockdown (Fig. 4F and G) leads to the op-
posite effect on LMNA splicing, as it reduces usage of the pro-
gerin 5′SS (Fig. 4H and I). Since SRSF1 has only a limited
affinity for the progerin SL, and since it did not activate the
progerin 5′SS in vitro, the effect observed upon siRNA knock-
down of SRSF1 might result from an indirect mechanism.
Given that in vivo transcription and splicing are coupled
(41), it is possible that SRSF1 depletion alters the transcription
rate of the RNA pol II (42) allowing better recognition of the
progerin 5′SS.
The SR proteins SRSF6 and SRSF1 have opposing
effect on the usage of the progerin 5′SS in primary
patients’ fibroblasts
To directly demonstrate the involvement of SRSF1 and SRSF6
in the regulation of the progerin 5′SS selection, we used fibro-
blasts isolated from HGPS patients. The levels of SRSF1 or
SRSF6 in these fibroblasts were reduced by RNAi-mediated
knockdown and the splicing profile of endogenous LMNA
was evaluated by RT–PCR using primers located in exon 8
and exon 12 to amplify both progerin and lamin A cDNAs.
Consistent with the results obtained with transfected reporter
constructs, the siRNA-mediated reduction in SRSF6
(Fig. 5B, panel SRSF6) greatly enhanced usage of the progerin
5′SS (Fig. 5A) with concomitant reduction in the lamin A 5′SS
utilization. In contrast, SRSF1 knockdown (Fig. 5B, panel
SRSF1) allowed slightly more lamin A mRNA production,
whereas progerin mRNA levels remained unchanged
(Fig. 5A). HGPS fibroblasts treated with siRNA targeting
SRSF6 accumulated slightly more progerin than HGPS fibro-
blasts treated with control siRNA, as judged by western blot-
ting with a lamin A/C antibody (Fig. 5B, panel lamin A/C).
However, in keeping with the RNA analysis, the effect of
SRSF1 knockdown on progerin expression is less visible.
Taken together, these observations established conclusively
that SRSF6 is directly responsible for repression of the pro-
gerin 5′SS in cells, in agreement with the effects of SRSF6
observed in in vitro splicing assays.
The progerin 5′SS splicing mechanism is conserved
in the mouse
The mouse LMNA gene has 83% identity in the open reading
frame when compared with human. Furthermore, the 20 nt
long sequences surrounding the progerin 5′SS in the mouse
(position 1817–1837) and human (position 1814–1834)
mRNAs only show one nucleotide difference (U 1831 in the
mouse instead of a C 1828 in human). Therefore, sequestration
of the putative progerin 5′SS in a secondary structure in the
mouse similar to that in human could be predicted (Fig. 6A),
and we verified this hypothesis experimentally (Fig. 6B). We
also showed that introduction of the human HGPS mutation
at the same position in the mouse as in the human progerin
SL (c.1827 C.U) strongly increased the accessibility of the
terminal loop as found for the human pre-mRNA, implying
that this conserved structure likely has a functional importance
(Fig. 6B) and that the progerin 5′SS could be used in mice.
To determine whether regulation of the progerin 5′SS was
similar in the two species, the HGPS C.T mutation was intro-
duced 6 nt downstream from the progerin 5′SS (c.1827 C.T)
in the Lmna mouse gene and mutated mice were generated by
homologous recombination (Osorio et al., submitted for publi-
cation). To evaluate the splicing profile of endogenous LMNA
transcripts, RNA extracted from different mouse tissues of WT
homozygous and heterozygous knock-in mice were submitted
to RT–PCR using primers located in exon 8 and exon 12 to
amplify both progerin and lamin A cDNAs (Supplementary
Material, Fig. S4a). This analysis was performed with
4-month-old mice because all the homozygous knock-in
mice LmnaG609/G609 died at this age (Osorio et al., submitted
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for publication). As expected, both heterozygous and homozy-
gous knock-in but not WT mice expressed progerin mRNA in
all tissues (Supplementary Material, Fig. S4a). Both RT–PCR
and western blot analysis of extracts from various tissues of
4-month-old homozygous knock-in mice (LmnaG609G/G609G)
confirmed that the steady-state levels of progerin are very
high compared with the lamin A level which is hardly detect-
able in most tissues (Supplementary Material, Fig. S4a and b,
G609G/G609G), implying that the expression of progerin
from the mutant allele is predominant over lamin A in most
tissues. Consistently, in heterozygous mice where both
alleles are expressed, the levels of lamin A and progerin are
comparable (Supplementary Material, Fig. S4a and b,
G609G/+), whereas in WT mice only lamin A is expressed
(Supplementary Material, Fig. S4a and b, +/+). LmnaG609G/
G609G mice also showed markedly reduced survival compared
with WT littermates, since all the homozygous mice died 4
months after birth (Osorio et al., submitted for publication).
Strikingly, LmnaG609G/+ mice were also short lived but sur-
vived longer than homozygous mice (8 months on average)
(Osorio et al., submitted for publication), suggesting that
Lmna splicing that favors progerin production can lead to
reduced growth and lifespan.
In order to study the contribution of SR protein to the regu-
lation of progerin production, we generated MEFs. MEFs iso-
lated from WT, heterozygous (LmnaG609G/+) and homozygous
(LmnaG609G/G609G) c.1827 C.T mutant embryos at embryonic
day 13.5 were harvested to analyze the RNA splicing ratio and
protein levels using RT–PCR and western blots, respectively
(Fig. 6C and D). As expected, both heterozygous and homozy-
gous but not WT MEFs expressed progerin mRNA (Fig. 6C)
and protein (Fig. 6D), demonstrating that the c.1827 C.T mu-
tation, like in human fibroblasts from progeria patients, acti-
vates the progerin 5′SS. In keeping with the PCR results,
more progerin is produced in the homozygous compared
with the heterozygous MEFs (Fig. 6D). However, while the
c.1827 C.T mutation induces a large decrease in the expres-
sion of the lamin A, it did not abolish its expression in the
homozygous MEFs, implying that alternative splicing is con-
trolling the balance between lamin A and progerin expression.
Consistent with previous results, immunofluorescence micros-
copy revealed that heterozygous and homozygous MEFs had
more misshapen nuclei with nuclear blebs than WT MEFs
(Fig. 6E and F). Thus, the c.1827 C.T mutation of the
mouse Lmna gene reproduces the splicing-dependent pheno-
type of fibroblasts from progeria patients.
Figure 5. SRSF6 prevents usage of progerin 5′SS in fibroblasts from progeria patients. (A) The levels of lamin A/C and progerin mRNA in treated cells with
scrambled siRNAs (lane 1) and with siRNA targeting either SRSF1 (lane 2) or SRSF6 (lane 3) were determined by RT–PCR using primers located in exon 9 and
exon 12. Right panel quantification of the ratio between truncated and full-length isoforms from two independent experiments of SRSF1 and SRSF6 siRNA
knockdown. (B) Depletions of SRSF1 or SRSF6 in fibroblasts from progeria patients using siRNAs (panels SRSF1 and SRSF6, respectively), and their
effects on lamin A, lamin C and progerin expression (panel Lamin A/C), as assessed by western blotting. Right panel quantification of the ratio between progerin
and lamin A from two independent experiments of SRSF1 and SRSF6 siRNA knockdown. The value of 1 is arbitrarily assigned to control siRNA samples.
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Next, to test whether SRSF1 and/or SRSF6 modulate the
progerin 5′SS in vivo, we reduced their levels with specific
siRNAs in LmnaG609G/+ MEFs. LmnaG609G/+ MEFs were
either mock-treated or transfected with siRNAs directed
against SRSF1 or SRSF6 and the corresponding proteins
levels were assessed by western blot analysis 5 days after
transfection. A reduction in both protein levels was observed
with their corresponding siRNAs (Fig. 7A, upper and lower
panels). To test the effect of SR protein depletion on the spli-
cing profile of LMNA primary transcripts expressed in the
Figure 6. The use of progerin 5′SS is conserved from the mouse to human. (A) Sequence comparison between the mouse (position 1817–1837) and human
(position 1814–1834) mRNAs corresponding to the progerin SL. (B) The secondary structure model proposed for WT (left) and mutated (right) mouse progerin
SL. The model was proposed based on thermodynamic considerations and on the results of the enzymatic digestions shown. T1, T2 and V1 RNase cleavages are
symbolized as in Figure 2. The structure representation shows all the bases used and the position of the progerin 5′SS is indicated. Autoradiographs show primer
extension analyses of the WT and the mutant c.1827C.U mouse progerin SL cleaved by increasing amounts of T1, T2 and V1 RNases. Lanes U, G, C and A
correspond to the sequencing ladder. Note good accessibility to T1 and T2 cleavage around the mutation. (C) Heterozygous (LmnaG609G/+) and homozygous
(LmnaG609G/G609G) MEFs carrying the equivalent splicing mutation in endogenous LMNA express increased amounts of progerin as shown at the RNA level
by RT–PCR using primers either side of the mutation and (D) at the protein level as shown by western blotting revealed with lamin A/C antibody. (E) Expression
of mouse progerin leads to nuclear abnormalities, as shown by immunofluorescence with anti-lamin A/C and Hoechst staining. Scale bars correspond to 10 mm.
(F) Quantification of nuclear abnormalities in WT (Lmna+/+), LmnaG609G/+ and LmnaG609G/G609G mutated fibroblasts at the indicated cell passages.
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corresponding fibroblasts, RT–PCR experiments were per-
formed with an oligonucleotide pair allowing amplification
of both lamin A and progerin isoforms. The results established
that siRNA-mediated reduction in SRSF6 protein levels is cor-
related to an effective increase in progerin both at the protein
(Fig. 7A, upper and lower panels) and mRNA levels (Fig. 7B,
upper and lower panels), whereas siRNA-mediated reduction
in SRSF1 leads to opposite effect (Fig. 7A and B, upper and
lower panels). Given that progerin accumulation was expected
to change the nuclear envelope of MEFs, we checked the
effect of these SR proteins depletion on nuclear morphology.
As predicted, depletion of SRSF6 was associated with more
misshapen nuclei, whereas SRSF1 depletion reduced the
number of misshapen nuclei. Taken together, these observa-
tions establish for the first time that SRSF6 and SRSF1 have
opposing effect on Lmna gene splicing.
DISCUSSION
In 2003, it was discovered that the silent mutation in exon 11
of the LMNA gene responsible for human progeria syndrome
allows production of progerin by inducing utilization of a
5′SS in the exon 11 (4,5). Although this phenomenon was
described long ago, the molecular basis for the age-associated
splicing alteration of the LMNA gene has not been elucidated.
Here we demonstrate that the 5′SS in the exon 11 of the LMNA
gene is engaged in a stable RNA structure which is probably
preventing its efficient recognition by the splicing machinery.
The progeria mutation induces some opening of the terminal
loop which may favor accessibility of the internal 5′SS and
facilitate U1 snRNP association. In addition, regulation of
the competition between the progerin 5′SS and lamin A 5′SS
by the SR proteins SRSF1 and SRSF6 is also modulated by
the mutation. The demonstration that these two characteristic
features are also conserved in the mouse further underlies
the importance of splicing repression to minimize progerin
production during aging.
It is indeed striking that the progerin 5′SS is conserved in
mammals over millions of years and that the single-point
mutation at the normally uninfluential +6 position leads to
the same dramatic changes in splicing. Our in vitro splicing
analyses of the WT and mutated LMNA pre-mRNA, performed
for the first time, showed that WT progerin 5′SS is a bona
fidae 5′SS, since it is moderately recognized from the WT
transcript, and strongly activated from the mutated transcripts,
as expected (Fig. 4). Interestingly, our observation of the util-
ization of the WT progerin 5′SS in the absence of the mutation
Figure 7. LMNA splicing regulation by the SR proteins SRSF1 and SRSF6 is conserved between the mouse and human. SRSF1 or SRSF6 was depleted in
LmnaG609G/+MEFs using siRNAs. Below each section, the quantifications are shown as bar charts. (A) Western blot showing depletion of SRSF1 or SRSF6
and its effect on the ratio of lamin A/C and progerin. (B) The splicing pattern of the LMNA gene in SRSF1 or SRSF6 depleted cells was determined by
RT–PCR and analysed as in Figure 5C. (C) Nuclear abnormalities in LmnaG609G/+ MEFs after SRSF1 or SRSF6 depletion, as shown by immunofluorescence
with anti-lamin A/C and Hoechst staining. Scale bars correspond to 30 mm. Percentage of nuclear abnormalities in siRNA-treated versus control cells is shown.
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is in agreement with several reports indicating that progerin
may be detected at low level during physiological aging
(10,15–17). Furthermore, the fact that the splicing at the pro-
gerin 5′SS can be also induced in WT fibroblasts using anti-
sense oligonucleotides against exon 11 sequences (43), and
that the splicing of WT and mutated LMNA transcripts is
modulated by SR proteins strongly supports the idea that the
progerin 5′SS is an alternative 5′SS. Therefore, the mutation
1824C.T reinforces a naturally weak 5′SS rather than
create a de novo 5′SS.
Interestingly, the progerin 5′SS in the WT exon 11 is
engaged in a stable SL structure (progerin SL), with a
compact terminal tetra-loop. This tight structuration likely pre-
vents its efficient recognition by the splicing machinery. In
contrast, the lamin A 5′SS is in a favorable non-structured
region (Fig. 2). The progeria mutation markedly increases
the accessibility of the terminal loop of the progerin SL,
which together with the slight increase in the intrinsic strength
of the progerin 5′SS by the C.U substitution is expected to
favor the recognition of the 5′SS by U1 snRNP. Indeed, it is
well known that RNA–RNA interaction preferentially initiates
through loop–loop or single strand–loop interactions (44).
Interestingly, we observed that the other mutation 1822
G.A in the human LMNA gene, which is associated with
HGPS (4,5), also leads both to an opening of the progerin
SL structure and an increased progerin 5′SS utilization. It
will be interesting to identify the kind of structuration of the
progerin SL terminal loop by structural analysis such as
NMR 3D structure analysis, since another single mutation in
this loop, 1825 G.A, was found to induce both an opening
of the loop structure and an increase in the progerin 5′SS util-
ization in vitro. We predict that the occurrence of this muta-
tion in the human LMNA gene may generate HGPS. In
support to the proposed role of the RNA structure in regulation
of the progerin 5′SS, it should be pointed out that there are
already well-documented examples for the involvement of
RNA secondary structure in the control of alternative splicing
(31,45,46). For example, the stability of a predicted SL struc-
ture at the 5′SS of the key Alzheimer’s protein tau regulates
usage of exon 10 (47,48) and the alternative exon of the key
adhesion gene fibronectin is highly influenced by secondary
RNA structure (31). Bioinformatics analyses indicate that
the splicing regulatory sequences are preferentially in a single-
stranded conformation, as this allows these sequences to inter-
act with RNA-binding proteins that mostly have a preference
for single-strand RNA (45). At present, it is unclear whether
SR proteins SRSF6 and SRSF1 that regulate the progerin
5′SS utilization are involved in the stabilization or disruption
of the identified RNA structure. According to the present
data, SRSF6 might stabilize the RNA structure around the pro-
gerin 5′SS, thereby, preventing SRSF1 from enhancing the
recruitment of the U1 snRNP. As transcription and splicing
are connected, the kinetics of elongating polymerase could
also influence the formation of RNA structures in connection
with SR protein concentrations (26,41).
Like other splicing mutations that are involved in the eti-
ology of human diseases, the HGPS mutation does not inacti-
vate LMNA gene expression completely, but rather gives rise
to a mixture of normal and aberrant isoforms. Transitions
between splicing isoforms are dynamic and depend on a
balance between factors that maintain a silent alternative
splice site and those that promote its activation, possibly in
a tissue-specific manner (19). Increased production of progerin
in the homozygous and heterozygous mice harboring the spli-
cing mutation triggers many of the features that appear early
on in humans with HGPS, such as slow growth, osteolytic
lesions in bone, osteoporosis, micrognathia and loss of
adipose tissue (Osorio et al., submitted for publication). In
contrast, consistent with previous reports (49) (Osorio et al.,
submitted for publication), no functional abnormalities were
associated with mice lacking lamin A and/or progerin expres-
sion, indicating that progerin, even at trace levels, could be
detrimental for lifespan. Given that progerin production is
under the control of both transcription and splicing of the
LMNA gene, the importance of splicing has escaped analysis
in previously described models (50,51). If changes in the
RNA structure and/or SR proteins concentrations occur prefer-
entially in some tissues but not others, one would expect that
progerin accumulation will also be different between tissues.
Our initial analysis of progerin expression in various tissues
of the mouse shows that this is indeed the case (Supplementary
Material, Fig. S4). In WT mice, where only lamin C and lamin
A are detected, it can be clearly seen that while the brain con-
tains roughly equivalent amount of both proteins, in all other
tissues the lamin A content is higher than lamin C. Also, the
brain accumulated less progerin than lamin C in both homozy-
gous and heterozygous knock-in mice. Consistent with the
RNA analysis, in heterozygous knock-in mice, it can be appre-
ciated that less progerin is expressed in both the brain and
spleen where the lamin A mRNA was higher than progerin
mRNA. In contrast, the heart of heterozygous mice accumu-
lated more progerin than any other tissue.
The detailed knowledge of the factors that are critical for
the activation described here and how they cooperate with
other spliceosomal components in a given tissue in the
HGPS-like mouse model will help the design of new thera-
peutic agents. The basis for targeting mutated RNA sequences
is straightforward and highly specific for a given gene because
it relies on antisense molecules base-paired to pre-mRNA to
prevent access of the splicing machinery to splice sites
(52,53). Combination of the RNA structure and binding of
SR proteins described here helps explain past successes and
failures of anti-sense oligonucleotides (ASOs) to modulate
alternative splicing within LMNA exon 11 (43,53). Converse-
ly, we show here that the region 50 nucleotides downstream of
the alternative donor site is fully accessible and may serve as
binding site for splicing regulators. Interestingly, targeting of
ASOs to that region was effective at triggering progerin pro-
duction from WT LMNA pre-mRNA (43,53). It has been pos-
tulated that this enhancement might be due to the ability of
ASOs to hide a binding site for SRSF5. Our in vitro comple-
mentation assay is in keeping with this postulate because
SRSF5 is shown to enhance the use of the LMNA 5′SS at
the expenses of progerin 5′SS (43) (data not shown). Our
finding that two SR proteins might have opposing effects on
progerin 5′SS utilization indicates that the efficiency of
ASOs to prevent splicing at this site will depend on the cellu-
lar concentration of the two SR proteins, making the outcome
of the effect of the ASOs less predictable. This does indeed
seem to be the case since in one study a morpholino ASO
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hybridizing to the progerin 5′SS was shown to be effective at
reducing the aberrant splicing, whereas another study using a
2′O methyl ASO had a negligible effect (43,54).
The new mouse model (Osorio et al., submitted for publica-
tion) will facilitate testing the outcomes of ASO treatment in
different tissues; it could also lead to development of a thera-
peutic strategy involving small molecules that target splicing
factors (53,55). This can be achieved either by lowering
their cellular levels or by interfering with their splicing enhan-
cing/repressing activity. Our data establish a proof of principle
that SR proteins could be therapeutic targets. RNAi-mediated
reduction in the SR protein SRSF1 levels led to a reduction in
progerin expression in heterozygous LmnaG609G/+ MEFs,
whereas SRSF6 knockdown aggravated the MEFs phenotype.
As SR protein knockdown is expected to have a pleiotropic
effect on gene expression and not only affect progerin expres-
sion, targeting of the activity of SR proteins on specific sub-
strates could be more attractive. Indeed, screening of
chemical libraries with ESE-dependent splicing substrates
resulted in the identification of indole derivatives as a class
of small molecule inhibitors of alternative splicing (56).
Rather than generally inhibiting splicing, these molecules
proved highly selective for splicing events mediated by differ-
ent classes of ESE sequences and are therefore less toxic.
Their selectivity is thought to depend on their interaction
with each SR protein (56,57). Further studies are now
ongoing to confirm the potency and lack of deleterious side-
effects of indole derivatives in the HGPS model.
The control of lamin A/progerin splicing switch of the
LMNA gene in the various tissues of the mouse will have an
important impact on the lifespan. Balancing this output in crit-
ical tissues will be a major determinant not only for therapeut-
ic action but also for establishing the longevity of mammalian
organisms.
MATERIALS AND METHODS
Ethics statement
All animal procedures were conducted in strict adherence with
the European Community Council Directive of 24 November
1986 (86-609/EEC).
Plasmids constructs
LMNA sequences (exon 11, intron 11 and exon 12) were PCR
amplified from WT and patient’s cell genomic DNA with spe-
cific forward and reverse primers. PCR fragments were
purified with Concert Rapid PCR purification system (Invitro-
gen) and subcloned at the BamHI and EcoRI restriction sites of
the bglo3S plasmid (39) to give the bGlo-LMNA constructs
used for in vitro splicing and transient transfection
experiments.
Cell lines, culture and transfection conditions
HeLa cells were grown in Dulbecco’s modified eagle medium
media (Gibco) complemented with 10% fetal calf serum and
antibiotics. They were transfected in six-well plates, at 50%
confluency (30% for siRNA experiments), using Dreamfect
(OZ biosciences) for plasmid DNA or oligofectamine (Invitro-
gen) for siRNAs, according to the manufacturer’s instructions.
For siRNA depletion of SR proteins, cells were treated for
72 h with siRNAs against hASF/SF2 (hSRSF1) or 96 h with
siRNAs against hSRSF6 (with two successive applications
carried out at 24 h interval). The mutant bGLo- LMNA
plasmid was transfected and incubated for 24 h before reco-
vering the cells. The siRNA sequences are available upon
request. MEFs were derived from embryos dissected 13.5
days after detection of vaginal plugs according to Nagy
et al. (58). Fetal livers and/or yolk sacs were used for PCR
genotyping. MEFs were transfected in six-well plates with
siRNA using oligofectamine (Invitrogen), according to the
manufacturer’s instructions. For siRNA depletion of SR pro-
teins, cells were treated for 72 h with siRNAs against
mSRSF1 or 96 h with siRNAs against mSRSF6 (with two suc-
cessive applications carried out at 24 h interval). The siRNA
sequences are available upon request.
Human HGPS fibroblasts AG01972 were purchased from
Coriell Cell Repository. They were cultured at 378C in
DMEM containing GlutaMAX, non-essential amino acids,
sodium pyruvate, 0.1 mM b-mercaptoethanol and 10% fetal
bovine serum. For siRNA depletion of SR proteins, cells
were treated for 72 h with siRNAs against SRSF1 or SRSF6.
The siRNA sequences are available upon request.
Expression of tagged SR proteins SRSF6-Flag and
SRSF1-His was performed after transfection of the corre-
sponding plasmid in the human embryonic kidney 293 cell
line expressing Epstein-Barr virus EBNA1 protein (293E)
according to the established protocol (59).
RNA and protein analysis
RNAs were extracted using TRI Reagent (Sigma-Aldrich).
The samples were treated with RNase-free DNase (RQ1,
Promega). Cellular RNA concentrations were quantified
by measuring optical absorption at 260 nm with a
nanodrop. 1.5 mg of RNA was reversed transcribed using
‘First strand cDNA synthesis’ kit (GE Healthcare biosciences)
with random hexamers. PCRs were carried out with 0.1 mM
dNTP mix, 1 mM MgCl2, 1× PCR buffer, 1.25 U of Taq
DNA polymerase (Invitrogen) and 0.2 mM of each of the
sense and antisense primers. Denaturation, annealing and
extension were performed at 94, 64 and 728C, respectively.
Each step lasted 30 s. PCRs were performed on a Master
cycler Gradient 96 thermocycler (Eppendorf) with 28 cycles.
These cycles were preceded by a 3 min denaturation at 948C
and terminated by a 2 min extension at 728C. Amplification
products were analyzed by 2% agarose gel electrophoresis
and visualized by ethidium bromide staining. The intensity
of the bands corresponding to the two mRNAs was quantified
using GeneSnap acquisition software and GeneTools analysis
software (Syngene). The ratio lamin A 5′SS/progerin 5′SS
from three independent transfection experiments was normal-
ized using the control sample of each series as a reference,
which gave a score for the choice of progerin 5′SS.
HeLa cell proteins were extracted in a buffer containing
50 mM Tris–HCl pH 6.8, 20 mM ethylenediaminetetraacetic
acid (EDTA), 5% sodium dodecyl sulfate (SDS), sonicated
briefly on ice and analysed by SDS–PAGE and western
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blotting. Proteins from MEFs and mouse tissues were
extracted in a buffer containing 63 mM Tris–HCl pH 7.5,
2% SDS, 5% b-mercaptoethanol and 8 M urea. Samples
were ground in a glass tissue grinder for additional 2 min
and then sonicated and centrifuged at 13 200g for 10 min at
48C. The supernatant was analyzed by western blotting
using 4–12% polyacrylamide BisTris gels (Invitrogen) for
electrophoresis and fractionated proteins were then transferred
to a nitrocellulose membrane. For western blotting, we used
the following antibodies with the corresponding dilutions:
anti g-tubuline (sigma) (1/1000); anti-ASF/SF2 (Invitrogen/
Zymed, catalog #32-4500); anti-SRSF6 (kind gift of Adrian
Krainer) (mAb 8-1-28 culture supernatant); anti-lamin A/C
(Santa Cruz, sc-20681); anti-mouse HRP (GE Healthcare)
and anti-rabbit HRP (GE Healthcare).
Immunofluorescence
MEFs were plated on glass cover slips at a confluence of 50%
before fixation in 3.7% formaldehyde in phosphate-buffered
saline (PBS) followed by a 5 min permeabilization in 0.1%
Triton X-100 in PBS. Cells were then incubated in PBS contain-
ing 3% bovine serum albumin (BSA) before staining with
primary antibodies as follows: rabbit polyclonal anti-lamin A/
C (N-18) (sc-6215 from Santa Cruz Biotechnology, Inc.) at
4 mg/ml in PBS–0.1% BSA, goat polyclonal anti-lamin B
(M-20) at 4 mg/ml in PBS–0.1% BSA (sc-6217 from Santa
Cruz Biotechnology, Inc.). Primary antibodies were revealed
with either an AlexaFluor546- or -488-conjugated anti-rabbit
or anti-goat antibody (Invitrogen). Nuclei were stained with
Hoechst 33 342 dye (1 mg/ml) (Sigma B2261). Cells were
then washed in PBS and mounted on glass slides in ‘ProLong
Gold Antifade’ Reagent (Invitrogen). Sixteen-bit fluorescent
images were captured with a MetaMorph-driven microscope
(Leica DM6000) using a Leica 40 HCX PL APO 1.25-0.75 oil
immersion objective (Leica) and a ‘CoolSNAP HQ2’ camera
(Photometrics). Individual images were further processed
using Adobe Photoshop software.
Recombinant proteins and in vitro and ex vivo
splicing assays
Recombinant SRSF1 and SRSF6 were produced and purified
from baculovirus-infected Sf9 cells as previously reported
(60). For in vitro splicing, radiolabelled RNAs were synthe-
sized by in vitro transcription in the presence of 50 U of T7
RNA polymerase (NEB), 2 mg of the suitable linearized plas-
mids and 50 mCi [a-32P] UTP (800 Ci/mmol) in 40 ml reac-
tions according to the manufacturer conditions. After DNase
(RQ1, PROMEGA) digestion, in vitro transcripts were purified
with sigma columns (Sigma, RTN10-1K) and quantified by
Cerenkov counting. Splicing reactions with HeLa nuclear
extracts (CilBiotech) and 20 fmol of radiolabelled transcripts
were performed under standard conditions as described previ-
ously (61). Spliced products were cleaned by proteinase
K-treatment and phenol extraction, and analyzed by 6%
polyacrylamide gel electrophoresis.
UV cross-linking
For UV cross-linking, radiolabelled RNAs were synthesized
by in vitro transcription in the presence of 20 U of SP6
RNA polymerase (NEB), 1 mg of the suitable linearized plas-
mids and 60 mCi [a-32P] GTP (800 Ci/mmol) in 20 ml reac-
tions according to the manufacturer’s instructions. In vitro
transcripts were purified by phenol-chloroform extraction,
verified by denaturing polyacrylamide-urea gel electrophoresis
and quantified by Cerenkov counting. HeLa nuclear extracts
were pre-incubated for 15 min at 378C in a 10 ml solution con-
taining 10 mM triethylamine (TEA) pH 8, 50 mM KCL, 0.1 mM
EDTA, 0.25 mM DTT, 10% glycerol, 7.5 mM ATP, 25 mM cre-
atine phosphate, 1 mM MgCl2 and 0.025 mg/ml of yeast tRNA.
One hundred femtomole of indicated radiolabelled RNA was
then added into 10 ml of interaction buffer (10 mM TEA pH
8, 50 mM KCL, 0.1 mM EDTA, 2.25 mM DTT, 12.6% glycerol,
0.75 mM ATP, 25 mM creatine phosphate, 1 mM MgCl2, 0.2%
NP40, 32 U of RNasin (PROMEGA) and 0.06 mg/ml of
BSA). Mixture reactions were then incubated 15 min at
308C, and subsequently transferred to 96-well plates.
Samples were irradiated for 20 min on ice with UV light
(254 nm) at a distance of 5 cm. After RNAse treatment,
20 ml of 5× SDS gel loading buffer was added in each
sample and cross-linked proteins were separated by 12%
SDS–PAGE. Gels were fixed (30 min in 50% methanol,
10% acetic acid, then 5 min in 7% methanol, 7% acetic
acid, 1% glycerol), dried and revealed by autoradiography.
For two-dimensional gel analysis of SR proteins, UV cross-
linked proteins were diluted in a buffer containing 7 M urea,
2 M thiourea, and 4% CHAPS, 4% IPG buffer and 10 mM
DTT. Samples were subjected to two-dimensional analysis
first with Immobiline Dry strips (pH 3-11 NL GE healthcare)
using an Ettan IPGphor3 IEF system (GE healthcare life
sciences) according to the manufacturer’s instructions. After
the second dimension electrophoresis, proteins were trans-
ferred onto nitrocellulose membranes. The membrane was
first revealed by autoradiography and then SRSF1 and
SRSF6 were detected with the above indicated antibodies,
followed by ECL staining.
Enzymatic and chemical probing of RNA secondary
structure
RNA 2-D structures in solution were probed as follows;
200 ng of transcripts dissolved at a 80 nM concentration in
buffer D (20 mM Hepes-KOH, pH 7.9, 100 mM KCl, 0.2 mM
EDTA pH 8.0, 0.5 mM DTT, 0.5 mM phenylmethylsulfonyl
fluoride, 20% (vol/vol) glycerol) were renatured by 10 min
heating at 658C, followed by slow cooling at room tempera-
ture with the addition of 1 ml of 62.5 mM MgCl2 to a final con-
centration of 3.25 mM MgCl2. After a 10 min pre-incubation at
room temperature, RNase T1 (0.02 or 0.0375 U/ml) or T2
(0.025 or 0.0375 U/ml) was added under conditions conducive
to cleavage of single-stranded segments. V1 RNase (2.5 ×
1023 or 5 × 1023 U/ml) was used to cleave double-stranded
and stacked residues. DMS [1 ml of a 1/4 or 1/8 (V/V)
DMS/EtOH solution] was employed to modify single-stranded
A and C residues and CMCT was used (4 or 5 ml of a 180 mg/
ml solution) to modify single-stranded U and to a lesser extent
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G residues. Reactions were stopped as previously described
(23). Cleavage and modification positions were identified by
primer extension (23). Stable secondary structures having
the best fit with experimental data were identified with the
Mfold software, version 8.1. Probing data were introduced
as a constraint in the search.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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